Welcome to our dedicated page for VASO SEC filings (Ticker: VASO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaso Corporation filings document formal disclosures for a diversified medical technology company with network services, professional sales services, and proprietary medical products. Recent Form 8-K reports cover material events such as subsidiary-related transactions, executive compensation arrangements, and amendments to the company’s bylaws.
Proxy and shareholder-meeting filings describe Vaso’s board elections, advisory executive-compensation votes, meeting procedures, common-stock voting matters, and governance provisions. The filing record also identifies the company’s OTCQX-listed common stock context, wholly owned subsidiary structure, and recurring disclosure topics tied to operating results, governance, material agreements, and corporate actions.
Vaso Corporation will hold its 2025 annual meeting on December 17, 2025 at 10:00 A.M. EST at Lever House, 390 Park Avenue, New York. Stockholders will vote on: (1) electing three Class II directors for three-year terms, (2) a non-binding Say on Pay advisory vote, and (3) a non-binding Say When on Pay vote on the frequency of Say on Pay.
The Board recommends voting FOR all director nominees, FOR Say on Pay, and for a three-year Say on Pay frequency. The record date is October 31, 2025, with 175,953,035 shares outstanding and entitled to vote. Officers and directors hold 43.85% of voting power and intend to vote consistent with these recommendations.
Holders may vote by Internet (www.proxyvote.com), phone (1-800-690-6903), mail, or in person. A quorum requires one-third of shares entitled to vote. The Board has determined that four of seven directors are independent under NASDAQ standards.